We're proud to receive a 2025 CDMO Leadership Award in the “Small Molecule Dosage Form - Global" category.
Clinical ancillary management expertise helps biopharma company oversee a large, global trial from start through finish.
Follow a biopharmaceutical company entering a Phase III trial that included 45 countries and an enrollment target of 4,000 patients in a randomized, double-blind, placebo-controlled study.
Learn more about how this company managed to: